

Table 1 Significantly enriched disease terms of PharmMapper predicted targets

Compound	Diseases	Gene Count
Morin	Atherosclerosis	6 (ABO, F2, Cbs, Esr1, INSR, VDR)
	Myocardial infarct RT 5	5 (ABO, F2, Cbs, Esr1, INSR)
	Coronary artery disease	4 (ar, F2, cbs, Esr1)
	Diabetes, Type 1	6 (ABO, ADAM33, AKR1B1, Ar, INSR, VDR)
	Acute myocardial infarction	2 (F2, Esr1)
Piperine	Atherosclerosis, Coronary	9 (HMGCR, ABO, bhmT, F2, INSR, MMP3, PPARA, PPARG, VDR)
	Atherosclerosis, Coronary hyperlipidemia	3 (Nr1h4, PPARA, PPARG)
	Myocardial infarct	7 (ABO, F2, INSR, MMP3, PPARA, PPARG, VDR)
	Obesity	7 (Ar, HSD11B1, PPARA, PPARG, Pnmt, ptpn1, VDR)
	Hypertension	8 (HSD11B1, INSR, MMP3, PPARG, PPARA, Pnmt, ptpn1, VDR)
Veratric acid	Atherosclerosis	5 (ACE, cbs, gstm1, NOS3, PCK1)
	Myocardial infarct	8 (ABO, ACE, F7, Cbs, CYP2C9, FGG, NOS3, wars)
	Essential hypertension	3 (ACE, NOS3, REN)
Syringic acid	Stroke	5 (Gp1ba, Mmp1, MMP3, Mmp9, PDE4D)
	Left ventricular remodeling	3 (Mmp1, MMP3, Mmp9)
	Angina	3 (Gp1ba, MMP3, Mmp9)
	Acute coronary syndrome atherosclerosis, Coronary	2 (MMP3, Mmp9)
	Myocardial infarct, Atherosclerosis	2 (MMP3, Mmp9)
Diosgenin	Atherosclerosis, Coronary hyperlipidemia	3 (NR1H3, PPARG, RXRA)
	Hypertension	10 (CYP2C8, Esr1, HSD11B1, INSR, MMP3, NR3C1, PPARG, ptpn1, REN, VDR)
	Atherosclerosis, Coronary	9 (F2, Esr1, INSR, Mmp2, MMP3,

NR3C1,PPARG, Procr, VDR)

Coronary artery disease

6 (ar, F2, Esr1, MMP2, MMP3, NR3C1)

Diabetes, type 2

10 (ar, Fabp6, HNMT, INSR, MET, MAOB, NR3C1, PPARG, ptpn1, VDR)

Myocardial infarct

6 (F2, CYP2C8, INSR, MMP3, PPARG, VDR)

Diosmetin

Obesity

5 (Ar, Esr1, Pnmt, ptpn1, VDR)

Diabetes, type 2

8 (AKR1B1, Ar, gck, MET, mtap, PCk1, ptpn1, VDR)

Sinapic acid

Diabetes, type 2

11 (Ar, F7, gck, HNMT, INSR, KIF11, NOS2, PCK1, ptpn1, PKLR, akt1)

Myocardial infarct

7 (ABO, BAT1, F7, Cbs, FGG, INSR, wars)

Coronary artery disease

4 (Ar, F7, Cbs, NOS2)

Fibrinogen heart disease, Ischemic tissue plasminogen activator level

2 (F7, FGG)
